Amgen buys KAI Pharmaceuticals for US$315m
Amgen is to acquire privately owned KAI Pharmaceuticals for US$315m in cash.
The South San Francisco-based firm’s leading product candidate, KAI-4169, is a novel agent being initially studied for the treatment of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD) who are on dialysis.
SHPT, a component of CKD mineral and bone disorder (MBD), is a common and serious complication for patients with CKD who are on dialysis. In addition to SHPT, KAI is conducting preclinical research on prehemodialysis applications of KAI-4169.
Amgen will acquire worldwide rights, excluding Japan, to KAI-4169. Ono Pharmaceutical Co holds the rights in Japan.
Amgen has provided a loan to enable Phase III development planning for KAI-4169 prior to closing.
Sean Harper, executive vice president of research and development at Amgen, said: ‘We are excited about acquiring KAI, as well as the opportunity to potentially deliver a novel therapy for chronic kidney disease patients on dialysis suffering from secondary hyperparathyroidism.’
Steve James, president and chief executive of KAI, added: ‘KAI and the nephrology community are excited by the additional clinical data we've generated for KAI-4169, and we are thrilled that Amgen shares our perspective on the differentiated profile and potential of this product candidate.’
Subscribe now to Manufacturing Chemist to get unrestricted online access to our exclusive content and receive our high quality magazine every month.